Brilliant Violet 421™ anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
EH12.2H7_BV421_1_040311
Human peripheral blood lymphocytes were stained with CD3 FITC and CD279 (clone EH12.2H7) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • EH12.2H7_BV421_1_040311
    Human peripheral blood lymphocytes were stained with CD3 FITC and CD279 (clone EH12.2H7) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • EH12.2H7_BV421_2_040311
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Avail. Save
329919 25 tests 148,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329920 100 tests 292,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human, African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Becton, Dickinson and Company and its affiliates. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. patent(s), pending patent applications and/or foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3 and immunohistochemical staining of paraformaldehyde fixed frozen sections13. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed
  2. Cao J, et al. 2018. Nat Commun. 9:77. PubMed
  3. Sayin I, et al. 2018. J Exp Med. 7:40286. PubMed
  4. Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed
  5. Ferrando-Martinez S, et al. 2018. J Clin Invest. 128:2089. PubMed
  6. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  7. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  8. Minagawa A, et al. 2018. Cell Stem Cell. 1.548611111. PubMed
  9. Levin MJ, et al. 2018. J Clin Invest. 128:4429. PubMed
  10. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
  11. Whitney JB, et al. 2018. Nat Commun. 9:5429. PubMed
  12. André P et al. 2018. Cell. 175(7):1731-1743 . PubMed
  13. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  14. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  15. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  16. Collinson–Pautz MR, et al. 2019. Leukemia. 33:2195. PubMed
  17. Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
  18. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  19. Pilkinton MA, et al. 2017. Vaccine. 35:329. PubMed
  20. Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed
  21. Mastelic-Gavillet B, et al. 2019. J Immunother Cancer. 7:257. PubMed
  22. Bradley T, et al. 2020. Nat Commun. 11:948. PubMed
  23. Han Q, et al. 2020. Cell Rep. 30:1553. PubMed
  24. Claiborne DT, et al. 2019. PLoS Pathog. 15:e1007981. PubMed
  25. Kim N, et al. 2020. Nat Commun. 2.045138889. PubMed
  26. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
  27. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  28. Karlsson J, et al. 2020. Nat Commun. 1.773611111. PubMed
  29. Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed
  30. Pacheco Y, et al. 2013. J Immunol. 191:2072. PubMed
  31. Buggert M, et al. 2014. J Immunol. 192:2099. PubMed
  32. Buggert M, et al. 2014. J Immunol. 192:4685. PubMed
  33. Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed
  34. Claiborne D, et al. 2015. Proc Natl Acad Sci U S A. 112:1480. PubMed
  35. Eberhardt K, et al. 2015. Clin Infect Dis. 61: 1615 - 1623. PubMed
  36. Lee J, et al. 2015. Clin Immunol. 159: 37-46. PubMed
  37. Paris R, et al. 2015. PLoS One. 10: 0144767. PubMed
  38. Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed
  39. Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed
  40. RY H, et al. 2016. Oncoimmunology. 6:e1249561. PubMed
  41. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  42. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  43. Geetha H. Mylvaganam, Daniel Rios 2017. Proc Natl Acad Sci U S A. 114(8):1976-1981. PubMed
  44. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  45. Gibellini L, et al. 2020. EMBO Mol Med. 12:e13001. PubMed
  46. Juno JA, et al. 2020. Nat Med. 26:1428. PubMed
  47. Lindesmith LC, et al. 2020. Cell Mol Gastroenterol Hepatol. 0.586805556. PubMed
  48. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  49. Riberdy JM, et al. 2020. Mol Ther Methods Clin Dev. 1.146527778. PubMed
  50. Wu VH, et al. 2020. JCI Insight. 5:00. PubMed
  51. de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed
  52. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
  53. Gannon PO, et al. 2020. Cytotherapy. 22(12):780-791. PubMed
  54. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  55. Nielsen CM, et al. 2021. Cell Reports Medicine. 2(3):100207. PubMed
  56. Routhu NK, et al. 2021. Immunity. 54(3):542-556.e9. PubMed
  57. Bergamaschi L, et al. 2021. Immunity. 54(6):1257-1275.e8. PubMed
  58. Kreutmair S, et al. 2021. Immunity. . PubMed
RRID
AB_10900818 (BioLegend Cat. No. 329919)
AB_10960742 (BioLegend Cat. No. 329920)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 2    Revision Date: 01.22.2015

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account